



ROSUVASTATIN - all strengths including 15mg and 30mg Film-coated Tablets

- **Indicated for** the treatment of primary hyperlipidemia and mixed dyslipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), while increasing high-density lipoprotein cholesterol (HDL-C).

Dossier with 5, 10, 15, 20, 30, 40mg is available for submission

Cost competitive

- This product is based on standard technology and is produced in Europe.

Simplified Therapy Set-Up

- Physicians benefit from improved titration options, making it especially relevant to achieve the target dose and consequent cholesterol levels while avoiding side effects of this lifelong treatment.

Differentiation from Competition

- Setting itself apart from competitors, this product offers unique differentiation.

Covering a full range of strengths, including 15mg and 30mg

Enhanced dosing flexibility for physicians: This allows physicians to adjust titration more effectively, optimizing treatment for individual patient needs

Low Competition: The 15mg and 30mg strengths are not yet available in all markets




Regulatory pathway



- EU dossier approved
- Reference medicinal product: Crestor, film-coated tablets from AstraZeneca
- Legal basis: Article 10(1) generic application for 5/10/20/40mg and Article 10(3) hybrid application for 15/30mg

Partnership options

- The product is available for out-licensing in select European markets

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

 Zentiva Group a.s.
U Kabelovny529/16, 102 00 Prague 10, Czech Republic

 Zent2U@zentiva.com
 +420 267243231

 www.Zent2U.com

ZENTIVA